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A B S T R A C T
A series of novel 4-butyl-arylpiperazine-3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives were synthesized and
evaluated for their 5-HT1A/D2 receptor affinity and serotonin reuptake inhibition. The compounds exhibited
high affinity for the 5-HT1A receptor, (especially 4d Ki = 0.4 nM) which depended on the substitution pattern at
the phenylpiperazine moiety. From this series screen, compound 4c emerged with promising mixed receptor
profiles for the 5-HT1A/D2 receptors and the serotonin transporter (Ki = 1.3 nM, 182 nM and 64 nM, respec-
tively).
1. Introduction
Serotonin (5-HT) regulates several physiological processes such as
mood, appetite and sleep [1]. Consequently, 5-HT neurotransmission
dysfunction is often observed in schizophrenia, depression, anxiety and
obsessive–compulsive disorder [2]. One hypothesis explaining the pa-
thophysiology of depression is the “monoamine hypothesis”. It states
that the functional deficiency of monoamines (5-HT, dopamine (DA)
and noradrenaline (NE)) seen in depression results from decreased
protein transporter activity and abnormalities in the neurotransmitter
function of receptors. A recent work [3] suggests that reversal of this
effect and restoration of 5-HT are possible using a multimodal treat-
ment approach which involves targeting many receptors of neuro-
transmitters at the same time. Of the multiple therapeutics used for the
treatment of depression, the selective serotonin reuptake inhibitors
(SSRIs) play a prominent role. The therapeutic effect that can be ob-
served after the administration of an SSRI drug is the sum of neuro-
chemical alterations taking place in the brain, including desensitization
of 5-HT1A autoreceptors, down-regulation of receptors for neuro-
transmitters, changes in signal transmission, neurotropism,
mobilization and an increase in neurogenesis in the hippocampus [1].
Despite comprehensive research on the development of pharma-
cotherapies against the disease, current anti-depressants are limited by
delayed onset of action, safety and efficacy issues [4]. Thus, there is a
need for better treatment strategies. One possible strategy to achieve
this goal is combining SSRIs with an agonist/antagonist activity at
various serotonin receptors.
The 5-HT1A receptor ligands seem to be particularly promising in
the treatment of mental diseases such as depression and schizophrenia
[5]. The 5-HT1A receptor belongs to the G protein-coupled receptors
and exists as an autoreceptor and a heteroreceptor. Its highest con-
centration is observed in the limbic system and raphe nuclei of the brain
stem, as well as in the cerebral cortex, thalamus, hypothalamus and
basal nuclei [4]. The 5-HT1A receptor activation by endogenous 5-HT or
local agonist application inhibits both serotonergic and non-ser-
otonergic neurons [6]. The simultaneous administration of SSRI and a
5-HT1A receptor agonist/partial agonist causes a rapid increase in
neurotransmission in the serotonergic system, via a postsynaptic re-
ceptor stimulation. The release of endogenous serotonin is inhibited by
a negative feedback loop activated by the stimulation of
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somatodendritic autoreceptors [7]. Recently, the STAR*D (Sequenced
Treatment Alternatives to Relieve Depression) study revealed that, in
patients unresponsive to SSRIs alone, treatment augmentation with
buspirone resulted in symptom remission. From a functional perspec-
tive, buspirone, a partial 5-HT1A receptor agonist, facilitates the de-
sensitisation of 5-HT1A autoreceptors, which may be a reason for the
increased clinical efficiency of SSRIs (Fig. 1) [8]. Recently, a combi-
natorial approach using serotonin transporter (SERT) inhibition with a
5-HT1A receptor agonism (SSRI/5-HT1A dual-activity) appeared to be a
viable therapeutic approach. Two excellent examples of such drugs are
vortioxetine and vilazodone [9].
Long-chain arylpiperazines (LCAPs) have established their position
as favourable scaffolds for 5-HT1A receptor binding. Buspirone is a
prototype medication in this chemical class of compounds (Fig. 1)
[14,15]. As a result of the redesign of buspirone, many compounds with
affinities for the 5-HT1A receptor have been obtained. For example,
Mokrosz et al. 1995, reported on a series of 4-(4-succinimidobutyl)pi-
perazine derivatives of buspirone analogues and NAN190, of which the
most important compounds were MM199, MM77 and MP359 (Fig. 2)
[16–23].
Further LCAP studies identified structural features important for
ligand binding with the 5-HT1A receptor, in particular the aryl ring at
the N1 atom of the piperazine framework [24]. These studies evaluated
the length and flexibility of the alkyl chain at the N4 position. In con-
trast, the influence of the amide or the imide group is controversial.
One study suggests they stabilise the ligand-receptor complex [14],
whereas others suggest little or no influence on receptor binding
[25,26]. Study data focusing on the binding of LCAPs to 5-HT1A re-
ceptors appear equivocal in terms of the significant effects of the var-
iations of the alkyl spacer (i.e. its length and conformational dynamics)
on pharmacological profiles of the compounds [27].
Numerous preclinical and clinical studies have indicated that dis-
turbances in central serotonin activity are key factors in depression
[5,28]. However, other monoaminergic neurotransmitters like DA have
also been implicated. Many symptoms observed in depression (e.g.
anhedonia) have been linked with dysfunction of DA metabolism,
especially with decreased tonic dopamine neuron firing by activation of
the infralimbic prefrontal cortex (ilPFC) [29]. It is accepted that 5-HT
receptors indirectly modulate dopamine release from neurons [30].
Moreover, drugs that simultaneously target D2 and 5-HT1A receptors
may be advantageous for the pharmacotherapy of schizophrenia
(Fig. 1) [31]. Clinical studies have shown that the co-administration of
5-HT1A agonists with typical or atypical neuroleptics may enhance the
antipsychotic effects of these latter drugs, especially in terms of redu-
cing cognitive deficits [32,33]. Despite numerous compounds with
various chemical scaffolds that have been synthesized as potential an-
tidepressant and antipsychotics, LCAPs remain one of the most versatile
drug templates with high affinities for 5-HT1A and D2 receptors [34,35].
As depression and schizophrenia are complex neurological disorders
with many different symptoms, introducing multi-target drugs with
polypharmacological profiles has become a widely used therapeutic
approach [36]. Nowadays, LCAPs with affinities for 5-HT1A/D2 re-
ceptors and/or serotonin reuptake inhibition are used as medication
and include; buspirone (anxiolytic), vilazodone (antidepressant),
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Fig. 1. Chemical structures of representative long-chain arylpiperazines (LCAPs) used as antidepressant and antipsychotics (taken/adapted from [10–13]).
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cariprazine, aripiprazole, lurasidone and brexpiprazole (neuroleptics)
(Fig. 1). Developing new multi-target antipsychotics and anti-
depressants, which act on dopaminergic and serotoninergic receptors
with balanced receptor activities, has been our research goal.
In our previous paper, we described the synthesis and biological
evaluation of a number of pyrrolidine-2,5-dione derivatives, with good
double binding to the 5-HT1A receptor and SERT [37]. In the current
study, we focused on increasing binding affinity for the 5-HT1A re-
ceptor, while maintaining high affinity for SERT (Fig. 3) in a group of
test compounds.
We have selected 1-{4-[4-(1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-
yl]butyl}-3-(1H-indol-3-yl)pyrrolidine-2,5-dione (AC015) as a re-
ference compound due to its promising double affinity for SERT and the
5-HT1A receptor (5-HT1A Ki = 12.5 nM; SERT Ki = 11.3 nM) (Fig. 3)
[37]. Here, we conducted a new exploratory study with the replace-
ment of the 3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole moiety with
arylpiperazine residues and synthesized derivatives (4a–m). As a con-
tinuation of our study on pyrrolidine-2,5-dione derivatives, we now
report on the design and synthesis of a new series of AC015 analogues
and 4-butyl-arylpiperazine-3-(1H-indol-3-yl)pyrrolidine-2,5-dione de-
rivatives. Since clinical and pre-clinical studies indicate that 5-HT1A and
D2 receptor ligands simultaneously exhibit serotonin reuptake inhibi-
tion, and that this combination may have a potential for treating mood
disorders, we evaluated the newly designed compounds for 5-HT1A/D2
receptor affinity and serotonin reuptake inhibition in radioligand
binding assays.
2. Results and discussion
2.1. Chemistry
The target compounds 4a–m were obtained via a three-step synth-
esis (Scheme 1). First, 3-(1H-indol-3-yl)pyrrolidine-2,5-dione (1) and 1-
(4-bromobutyl)-3-(1H-indol-3-yl)pyrrolidine-2,5-dione (2) were syn-
thesized according to a previously described procedure (for more in-
formation see supplementary materials and [37–40]). Macor et al. [40],
first described the synthesis mechanism of 3-(1H-indol-3-yl) pyrroli-
dine-2,5-dione in acetic acid. They noted that a one-step reaction of
maleimide with 1H-indole to form a CeC bond is only possible when it
is carried out in an acid solvent. They reported that maleimide is ac-
tivated by the acid which increases its acceptor reactivity in the Michael
addition. According to Henon et al. and Bergman et al. [38,39] in some
cases, the side product 5,13-dihydro-6H-indolo[3,2-a]pyrrolo[3,4-c]
carbazole-6,8(7H)-dione was isolated along with compound 1. Future
study showed that, in order to avoid this side product, it is important to
carry out the reaction at the boiling point of the solvent (117–118 °C for
glacial acetic acid), and the molar ratio between maleimide and indole
should be 3:1. The alkylation agent (dibromobutane) was used in a
large excess (9 mol) in the N-alkylation step in order to avoid the re-
action of disubstitution leading to N,N-(butane-1,4-diyl)bisimides. The
final compounds 4a–m were obtained by N-alkylation of the inter-
mediate 2 with the appropriate arylpiperazines 3a–m (Scheme 1) [37].
2.2. In vitro receptor affinity and structure-activity relationship (SAR)
determination
The synthesized compounds were tested for their in vitro affinity for
the 5-HT1A and D2 receptor and inhibition of SERT using a radioligand
binding assay, according to procedures described in the experimental
section. The results are presented in Table 1.
The series 4a–m was designed to achieve compounds with high
affinities for 5-HT1A, with additional SERT and/or D2 receptor activ-
ities. The chemical structure of our compounds meets the criteria of the
classical pharmacophore for monoaminergic receptor ligands consisting
of the protonated amine anchored by Asp3.32 (for review see [41]) and
specific hydrophobic recognition involving aromatic interaction (CH–π
or π–π) with the Phe6.51/Phe6.52/Trp6.48 aromatic cluster. Ad-
ditionally, the terminal fragment connected with the basic centre via
the alkylene linker forms the aromatic and H-bond interactions and
stabilizes ligand binding in the second transmembrane pocket between
TMHs 7–3 (involving specific amino acids characteristic for serotonin
and dopamine receptors) [41]. Our previous docking study [37] of the
reference compound AC015 to the 5-HT1A binding site revealed that the
succinimide ring (specifically, the carbonyl oxygen atom) forms a hy-
drogen bond with Thr196 (2.18 Å) and the position of AC015 inside the
receptor binding pocket is further stabilized by π–π interactions be-
tween Phe112 and the indole ring [37]. Further, the docking study of
AC015 to the SERT binding pocket showed formation of a hydrogen
bond between the Arg104 residue and the carbonyl oxygen atom of the
ligand (2.25 Å). As shown in Table 1, all compounds displayed high
affinities for 5-HT1A, with Ki values ranging from 0.4 to 44.0 nM.
Moreover, most of the compounds exhibited dual 5-HT1A/SERT activ-
ities, in particular compound 4b (5-HT1A Ki = 25 nM, SERT
Ki = 26 nM). These results proved that the chemical structure of the
investigated compounds was well justified.
A previous report in the field [42] demonstrated significant inter-
actions between halogen substituents in the phenylpiperazine ring and
the binding site of the 5-HT1A receptor, and this modification therefore
attracted our attention in this study. More specifically, the role of the
halogens has been recently assigned to stabilise ligand–receptor
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Fig. 3. Structural features of previously synthesized reference compound AC015 and newly synthesized LCAPs (4a–m).
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complexes via the formation of specific halogen bonds [43]. The
binding data revealed that compounds having chlorine and fluorine
atoms attached to the phenyl displayed similar, high affinities for the 5-
HT1A receptor. The most potent were the ortho-substituted phenylpi-
perazines (PhPs), especially the 2-F-PhP derivative 4d (5-HT1A
Ki = 0.4 nM). The introduction of substituents in the para position
reduced the binding affinity for 5-HT1A receptors. When we compared
pairs of para- and ortho-derivatives, the ortho analogues displayed re-
markably higher affinities for the 5-HT1A receptor: chloro derivatives
4a (Ki = 1.6) versus 4b (Ki = 25.0); fluoro derivatives 4d (Ki = 0.4)
versus 4e (Ki = 42.0) and methoxy derivatives 4i (Ki = 1.4) versus 4j
(Ki = 44.0). This observation is in agreement with the previously
published data that substituents in para-position caused unfavorable
steric interactions with the 5-HT1A receptor binding site [17,44,45].
Partyka et al., described an in silico experimental study for azinesulfo-
namides of LCAP derivatives indicating a perturbation of ligan-
d–receptor complex stability (a lack of interaction with Asp3.32 in 5-
HT1A binding pocket), in both 4-F-PhP and 4-Cl-PhP derivatives [42].
This may explain the observed decrease of affinity of the investigated
para substituted compounds.
Interestingly, the para-derivatives showed a slightly increased in-
hibition of SERT, which resulted in compounds with double binding to
5-HT1A/SERT – 4b (5-HT1A Ki = 25 nM, SERT Ki = 26 nM) and 4j (5-
HT1A Ki = 44 nM, SERT Ki = 30 nM). In contrast, compounds 4i, 4l
and 4m, with a 2-methoxyphenyl, pyrimidine or pyridine substituent,
respectively, exhibited high 5-HT1A receptor potency, but negligible
inhibition of SERT. Replacement of the chlorine atom with fluorine was
not preferred for the interaction with SERT; 4a: (SERT) Ki = 43 nM
versus 4d: (SERT) Ki = 128 nM and 4b: (SERT) Ki = 26 nM versus 4e:
(SERT) Ki = 102 nM. In summary, substitution at the ortho-position of
the phenylpiperazine moiety was beneficial for 5-HT1A binding, the
para-position increased the affinity for SERT and optimal double
binding to 5-HT1A /SERT was observed for compound 4b (4-Cl-PhP
derivative).
It is worth noting that in this series, compound 4c, a 2,3-diCl-PhP
derivative, was classified as a 5-HT1A/D2/SERT multi-receptor ligand,
with high affinity for all of these receptors (Ki = 1.6 nM, 64 nM and
183 nM, respectively). The analogue with a methoxy group at the ortho-
position displayed affinity for the D2 receptor (4i Ki = 258 nM), which
was in agreement with the literature data [25,46]. The ortho-methoxy
function is known to be important for constraining the conformation by
its ability to form one additional H-bond in the D2R binding pocket
[47]. The para-substituted PhPs (compounds 4b, 4e, 4j) were sig-
nificantly less active in D2 receptor binding assays than their ortho-
counterparts. According to the previous study [47], substituents in
position 2 and 3 of phenylpiperazine are well tolerated, especially
electron donor groups such as methoxy. On the other hand, regardless of
their size, the 4-substituents are not beneficial for D2R binding [48].
Šukalović et al., explain this as a result of an unfavorable steric inter-
action of para substituents with Phe178, Tyr216 and Trp182 in the
receptor binding pocket. Therefore, the formation of a salt bridge be-
tween Asp86 and the protonated nitrogen of the piperazine ring, which
is crucial for L–R complex stability, is hindered [47].
3. Conclusions
In this study, a series of new 4-butyl-arylpiperazine-3-(1H-indol-3-
yl)pyrrolidine-2,5-dione derivatives (4a–m) were synthesized and
evaluated as 5-HT1A ligands, with additional serotonin reuptake in-
hibition and/or D2 receptor activity. All tested compounds displayed
high affinities for 5-HT1A, with Ki values ranging from 0.4 to 44 nM.
SAR studies revealed that the affinities of the series compounds for 5-
HT1A, SERT and D2 receptors were highly dependent on substitution
patterns of the phenylpiperazine moiety. Moreover, compounds 4a, 4b,
4j and 4k appeared to be ideal starting points for SSRI/5-HT1A dual-
activity agents.
Finally, we identified compound 4c, a potent, mixed 5-HT1A/D2/
SERT receptor ligand. This compound appears promising in light of the
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complexity of CNS disorders and mono-therapy limitations. Overall,
these data may merit further in vitro studies of compound 4c as a po-
tentially new multi-target ligand. Such studies will ultimately pave the
way in determining its potential in vivo antidepressant and/or anti-
psychotic activity in animal models.
4. Experimental section
4.1. Chemistry
4.1.1. General
All solvents and reagents were purchased from commercial sources
and were used without future purification. Melting points were de-
termined on an Electrothermal IA9200 apparatus (Cole-Parmer Ltd.,
Stone, Staffordshire, UK) with open capillary tubes and were un-
corrected. The purity (> 95%) and homogeneity of the compounds
were routinely confirmed. Bruker AVANCE III HD 500 MHz (Bruker
BioSpin, Rheinstetten, Germany) (500 MHz for 1H NMR, 125 MHz for
13C NMR), Varian INOVA 500 MHz (Varian, Palo Alto, CA, USA)
(500 MHz for 1H NMR, 125 MHz for 13C NMR) and Agilent 400-MR
DD2 400 MHz (Agilent, USA) spectrometer in CDCl3 or DMSO‑d6.
Chemical shifts (δ) were expressed in parts per million (ppm) relative to
tetramethylsilane used as the internal reference. The following ab-
breviations are used to describe peak patterns where appropriate: s
(singlet), bs (broad singlet), d (doublet), dd (doublet of doublets), t
(triplet), td (triplet of doublets), pt (pseudo triplet), 4d (quartet of
doublets), m (multiplet), q (quartet), qu (quintet), * – coupling with
fluorine nucleus. Coupling constants (J) are in hertz (Hz).
The High-Resolution Mass Spectrometry (HRMS) was performed
using Micromass LCT TOF (Waters Corporation, Milford, MA, USA)
mass spectrometer equipped with ESI ionization source, TOF analyser
and MCP detector. Samples as 1 mg/L concentration of tested com-
pounds were prepared in methanol. MS detection settings were as fol-
lows: source temperature 80 ˚C, desolvation temperature 150 ˚C, des-
olvation gas flow rate 200 L/h, cone gas flow 100 L/h, capillary
potential 3.50–5.00 kV, cone potential 26–50 V, extraction cone po-
tential 4–20 V, RF Lens 260–350 V. Nitrogen was used for both neb-
ulizing and drying gas. The data were obtained in a scan mode ranging
from 20 to 2000 m/z in time 1.0 s intervals. Data acquisition software
was MassLynx V 3.5 (Waters).
Flash column chromatography was carried out on Merck silica gel
60 (230–400 mesh ASTM) using dichloromethane/methanol as the
solvent (98:2 v/v). Thin layer chromatography was run on Merck silica
gel (Kieselgel 60 F254) plates, with mobile phases of dioxane, toluene,
ethanol and 25% NH4OH (6.0:3.2:0.5:0.2, v/v) or chloroform, me-
thanol, diethyl ether and NH4OH (18.0:4.0:3.6:0.4). Compounds were
visualized by UV light (254 nm). Room temperature refers to 20–25 °C.
Intermediate 1-(4-bromobutyl)-3-(1H-indol-3-yl)pyrrolidine-2,5-dione (2)
was obtained following the protocol described in our previous paper
(for more information see supplementary materials) [37]. Reagents:
maleimide and arylpiperazines derivatives (3a–m) were purchased
from common commercial suppliers and were utilized without further
purification. Atom numbering, 1H NMR and 13C NMR spectra of all
synthesized compounds is available in supplementary materials.
4.1.2. General procedure for the synthesis of arylpiperazine derivatives
(4a–m)
A mixture of 1-(4-bromobutyl)-3-(1H-indol-3-yl)pyrrolidine-2,5-
dione (2) (1.0 mmol), the appropriate arylpiperazines (4a–m)
(1.1 mmol), K2CO3 (2 mmol), a catalytic amount of KI and 50 mL
acetonitrile was stirred and refluxed for 4–5 h. Reaction time was
monitored using TLC. After cooling, the mixture was filtered, and the
filtrate was evaporated to dryness. The crude residue was purified by
flash chromatography using CH2Cl2/MeOH (98:2 v/v) as an eluent.
Proper fractions were identified by TLC and evaporated to dryness
giving analytically pure compounds 4a–m.
4.1.2.1. 1-(4-(4-(2-chlorophenyl)piperazin-1-yl)butyl)-3-(1H-indol-3-yl)
pyrrolidine-2,5-dione (4a). The title compound was isolated as a yellow
solid. Yield: 88.0% (0.41 g); m.p. 70–78 °C (melts with decomposition);
ESI-HRMS m/z calcd for C26H29ClN4O2H (M+H)+ 465.2057, found:
465.2070; 1H NMR (500 MHz, DMSO‑d6) δ: 4.37 (C3H, dd, 3J1 = 9.0,
3J2 = 5.0), 2.83 (C4H(1), dd, 2J = 18.0, 3J = 5.0), 3.25 (C4H(2), dd,
2J = 18.0, 3J = 9.5), 7.34 (C2′H, d, 3J = 2.5), 7.41–7.36 (C4′H, C7′H,
C3″H, m), 7.01–6.97 (C5′H, m)), 7.12–7.07 (C6′H, m), 3.49 (C1xH2, t,
3J = 7.0), 1.57 (C2xH2, q, 3J = 7.0), 1.43 (C3xH2, q, 3J = 7.0), 2.33
(C4xH2, t, 3J = 7.0), 2.48 (CaH2, CdH2, bs), 2.94 (CbH2, CcH2, bs),
7.05–7.01 (C4″H, m), 7.31–7.25 (C5″H, m), 7.13 (C6″H, dd, 3J = 8.0,
4J = 1.5), 11.05 (N1′H, bs); 13C NMR (125 MHz, DMSO‑d6) δ: 178.4
(C2), 37.6 (C3), 35.9 (C4), 176.7 (C5), 125.8 (C2′), 111.8 (C3′), 118.3
Table 1
5-HT1A, SERT and D2 receptor binding affinities of arylpiperazine derivatives
4a–m.
N
H
O
O
N
N N R
Compound R Ki ± SEM [nM] D2
5-HT1A SERT
4a Cl 1.6 ± 0.1 43 ± 3.2 432 ± 27
4b
Cl
25 ± 2.3 26 ± 2 > 5000
4c Cl Cl 1.3 ± 0.3 64 ± 7.6 182 ± 18
4d F 0.4 ± 0.03 128 ± 18.7 404 ± 42
4e
F
42 ± 4.5 102 ± 5.3 > 5000
4f CF3 5 ± 0.5 70 ± 6.9 729 ± 67
4g 1.9 ± 0.2 98 ± 8 962 ± 61
4h 1.5 ± 0.1 62 ± 7.8 600 ± 56
4i H3CO 1.4 ± 0.1 276 ± 21.3 258 ± 7
4j
OCH3
44 ± 5.5 30 ± 2.3 Not converged
4k 42 ± 3 28 ± 1.9 Not converged
4l 22.6 ± 1.9 496 ± 35 NT
4m 2.5 ± 0.2 521 ± 42 NT
Serotonin 1.2 ± 0.07 NT NT
Imipramine NT 2.0 ± 0.1 NT
Haloperidol NT NT 7.5 ± 0.3
NT – not tested.
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(C3′a), 118.8 (C4′), 121.4 (C5′), 123.5 (C6′), 110.8 (C7′), 136.5 (C7′a),
38.1 (C1x), 25.2 (C2x), 23.6 (C3x), 57.3 (C4x), 52.8 (Ca, Cd), 50.9 (Cb,
Cc), 149.1 (C1″), 127.6 (C2″), 130.3 (C3″), 123.8 (C4″), 128.0 (C5″),
120.8 (C6″).
4.1.2.2. 1-(4-(4-(4-chlorophenyl)piperazin-1-yl)butyl)-3-(1H-indol-3-yl)
pyrrolidine-2,5-dione (4b). The title compound was isolated as a
yellowish solid. Yield: 82.8% (0.39 g); m.p. 72–75 °C; ESI-HRMS m/z
calcd for C26H29ClN4O2Na (M+Na)+ 487.1877, found: 487.1863; 1H
NMR (500 MHz, CDCl3) δ: 4.27–4.22 (C3H, m), 2.90 (C4H(1), dd,
2J = 18.0, 3J = 5.0), 3.22 (C4H(2), 2J = 18.0, 3J = 9.5), 7.00 (C2′H,
dd, 3J = 2.5, 4J = 0.5), 7.42 (C4′H, dd, 3J = 7.5, 4J = 1.0), 7.14–7.09
(C5′H, m), 7.23–7.16 (C6′H, m), 7.33 (C7′H, dt, 3J = 8.0, 4J = 1.0),
3.65 (C1xH2, t, 3J = 7.5), 1.74–1.65 (C2xH2, m), 1.61–1.50 (C3xH2, m),
2.41 (C4xH2, t, 3J = 7.5), 2.55 (CaH2, CdH2, t, 3J = 5.0), 3.12 (CbH2,
CcH2, t, 3J = 5.0), 6.81 (C2″H, C6″H, dt, 3J = 9.0, 4J = 3.5), 7.19
(C3″H, C5″H, dt, 3J = 9.0, 4J = 3.5), 8.51 (N1′H, bs), 13C NMR
(125 MHz, CDCl3) δ: 178.3 (C2), 38.2 (C3), 36.3 (C4), 176.5 (C5), 118.5
(C2′), 111.4 (C3′), 125.7 (C3′a), 122.2 (C4′), 120.1 (C5′), 122.7 (C6′),
111.7 (C7′), 136.6 (C7′a), 38.9 (C1x), 25.8 (C2x), 24.1 (C3x), 57.9 (C4x),
53.0 (Ca, Cd), 49.1 (Cb, Cc), 149.9 (C1″), 117.2 (C2″, C6″), 128.9 (C3″,
C5″), 124.4 (C4″).
4.1.2.3. 1-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-3-(1H-indol-3-
yl)pyrrolidine-2,5-dione (4c). The title compound was isolated as an
orange solid. Yield: 79.1% (0.40 g); m.p. 65–75 °C (melts with
decomposition); ESI-HRMS m/z calcd for C26H29Cl2N4O2 (M+H)+
499.1655, found: 499.1668; 1H NMR (500 MHz, DMSO‑d6) δ: 4.36
(C3H, dd, 3J1 = 9.5, 3J2 = 5.0), 2.84 (C4H(1), dd, 2J = 18.0,
3J = 5.0), 3.25 (C4H(2), dd, 2J = 18.0, 3J = 9.5), 7.34 (C2′H, d,
3J = 2.0), 7.42–7.36 (C4′H, C7′H, m), 7.02–6.96 (C5′H, m), 7.30–7.26
(C6′H, C5″H, m), 3.49 (C1xH2, t, 3J = 7.0), 1.57 (C2xH2, q, 3J = 7.0),
1.43 (C3xH2, q, 3J = 7.0), 2.33 (C4xH2, t, 3J = 7.0), 2.48 (CaH2, CdH2,
bs), 2.94 (CbH2, CcH2, bs), 7.13–7.07 (C4″H, C6″H, m), 11.06 (N1′H,
bs, 3J = 1.5); 13C NMR (125 MHz, DMSO‑d6) δ: 178.4 (C2), 37.6 (C3),
35.9 (C4), 176.6 (C5), 118.4 (C2′), 111.8 (C3′), 126.0 (C3′a), 121.4
(C4′), 119.5 (C5′), 123.4 (C6′), 110.8 (C7′), 136.5 (C7′a), 38.1 (C1x),
25.2 (C2x), 23.6 (C3x), 57.2 (C4x), 52.8 (Ca, Cd), 50.9 (Cb, Cc), 151.2
(C1″), 124.3 (C2″), 132.6 (C3″), 125.8 (C4″), 128.4 (C5″), 118.8 (C6″).
4.1.2.4. 1-(4-(4-(2-fluorophenyl)piperazin-1-yl)butyl)-3-(1H-indol-3-yl)
pyrrolidine-2,5-dione (4d). The title compound was isolated as an
orange solid. Yield: 93.2% (0.42 g); m.p. 148–149 °C; ESI-HRMS m/z
calcd for C26H29FN4O2H (M+H)+ 449.2353, found: 449.2339; 1H NMR
(500 MHz, DMSO‑d6) δ: 4.37 (C3H, dd, 3J1 = 9.0, 3J2 = 4.5), 2.83
(C4H(1), dd, 2J = 18.0, 3J = 5.0), 3.25 (C4H(2), dd, 2J = 18.0,
3J = 9.5), 7.34 (C2′H, d, 3J = 2.0), 7.44–7.36 (C4′H, C7′H, m),
7.04–6.90 (C5′H, C4″H, C6″H, m), 7.15–7.05 (C6′H, C3″H, C5″H, m),
3.49 (C1xH2, t, 3J = 7.0), 1.57 (C2xH2, q, 3J = 7.0), 1.43 (C3xH2, q,
3J = 7.5), 2.32 (C4xH2, t, 3J = 7.0), 2.47 (CaH2, CdH2, bs), 2.97 (CbH2,
CcH2, bs), 11.06 (N1′H, bs); 13C NMR (125 MHz, DMSO‑d6) δ: 178.4
(C2), 37.6 (C3), 35.9 (C4), 176.6 (C5), 125.9 (C2′), 111.8 (C3′), 118.4
(C3′a), 118.8 (C4′), 121.4 (C5′), 123.4 (C6′), 110.8 (C7′), 136.5 (C7′a),
38.1 (C1x), 25.2 (C2x), 23.6 (C3x), 57.3 (C4x), 52.7 (Ca, Cd), 50.1 (Cb,
Cc), 139.9 (C1″, d*, 2J = 8.3), 154.9 (C2″, d*, 1J = 244.3), 115.8 (C3″,
d*, 2J = 20.5), 122.2 (C4″, d*, 3J = 7.9), 124.8 (C5″, d*, 4J = 3.3),
119.1 (C6″, d*, 3J = 3.0).
4.1.2.5. 1-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)-3-(1H-indol-3-yl)
pyrrolidine-2,5-dione (4e). The title compound was isolated as a yellow
oil at room temperature. Yield: 86.3% (0.39 g); ESI-HRMS m/z calcd for
C26H29FN4O2H (M+H)+ 449.2353, found: 449.2339; 1H NMR
(500 MHz, CDCl3) δ: 4.29–4.24 (C3H, m), 2.92 (C4H(1), dd,
2J = 18.5, 3J = 5.0), 3.24 (C4H(2), dd, 2J = 18.5, 3J = 9.5), 7.05
(C2′H, d, 3J = 2.5), 7.42 (C4′H, dd, 3J = 8.0, 4J = 0.5), 7.14–7.10
(C5′H, m), 7.24–7.19 (C6′H, m), 7.35 (C7′H, dt, 3J = 8.0, 4J =
5J = 1.0), 3.65 (C1xH2, t, 3J = 7.0), 1.70 (C2xH2, q, 3J = 7.5), 1.56
(C3xH2, q, 3J = 7.5), 2.42 (C4xH2, t, 3J = 7.5), 2.57 (CaH2, CdH2, pt),
3.09 (CbH2, CcH2, pt), 6.89–6.83 (C2″H, C6″H, m), 6.98–6.92 (C3″H,
C5″H, m), 8.43 (N1′H, bs); 13C NMR (125 MHz, CDCl3) δ: 178.2 (C2),
38.2 (C3), 36.3 (C4), 176.5 (C5), 125.7 (C2′), 111.5 (C3′), 118.5 (C3′a),
120.1 (C4′), 122.2 (C5′), 122.7 (C6′), 111.7 (C7′), 136.6 (C7′a), 38.9
(C1x), 25.8 (C2x), 24.1 (C3x), 57.9 (C4x), 53.2 (Ca, Cd), 50.1 (Cb, Cc),
147.9 (C1″, d*, 4J = 2.3), 117.8 (C2″, C6″, d*, 3J = 7.7), 115.5 (C3″,
C5″, d*, 2J = 22.0), 157.1 (C4″, d*, 1J = 238.9).
4.1.2.6. 3-(1H-indol-3-yl)-1-(4-(4-(3-(trifluoromethyl)phenyl)piperazin-
1-yl)butyl)pyrrolidine-2,5-dione (4f). The title compound was isolated as
an orange solid. Yield: 73.4% (0.37 g); m.p. 63–70 °C; ESI-HRMS m/z
calcd for C27H29F3N4O2H (M+H)+ 499.2321, found: 499.2311; 1H
NMR (500 MHz, CDCl3) δ: 4.32–4.23 (C3H, m), 2.93 (C4H(1), dd,
2J = 18.5, 3J = 5.0), 3.25 (C4H(2), dd, 2J = 18.0, 3J = 9.5), 7.10–7.01
(C4″H, C6″H, C2′H, C2″H, m), 7.44 (C4′H, dd, 3J = 8.0, 4J = 1.0),
7.17–7.00 (C5′H, m), 7.24–7.19 (C6′H, m), 7.36 (C7′H, dt, 3J = 8.5,
4J = 5J = 1.0), 3.66 (C1xH2, t, 3J = 7.0), 1.79–1.64 (C2xH2, m), 1.56
(C3xH2, q, 3J = 7.5), 2.42 (C4xH2, t, 3J = 7.5), 2.57 (CaH2, CdH2, pt),
3.21 (CbH2, CcH2, pt), 7.33 (C5″H, t, 3J = 8.0), 8.35 (N1′H, bs); 13C
NMR (125 MHz, CDCl3) δ: 178.2 (C2), 38.2 (C3), 36.3 (C4), 176.5 (C5),
125.7 (C2′), 111.5 (C3′), 118.5 (C3′a), 120.1 (C4′), 122.2 (C5′), 122.7
(C6′), 111.7 (C7′), 136.6 (C7′a), 38.9 (C1x), 25.7 (C2x), 24.1 (C3x), 57.8
(C4x), 53.0 (Ca, Cd), 48.6 (Cb, Cc), 151.3 (C1″), 112.1 (C2″, q*,
3J = 3.9), 131.4 (C3″, q*, 2J = 31.7), 115.7 (C4″, q*, 3J = 3.8),
129.5 (C5″), 118.6 (C6″), 124.3 (C6, q*, 1J = 272.6).
4.1.2.7. 3-(1H-indol-3-yl)-1-(4-(4-(o-tolyl)piperazin-1-yl)butyl)
pyrrolidine-2,5-dione (4g). The title compound was isolated as a yellow
solid. Yield: 80.5% (0.36 g); m.p. 62–76 °C (melts with decomposition);
ESI-HRMS m/z calcd for C27H32N4O2H (M+H)+ 445.2604, found:
445.2615; 1H NMR (400 MHz, CDCl3) δ: 4.30 (C3H, 4d, 3J1 = 9.5,
3J2 = 4.9, 4J = 0.9), 3.98–2.88 (C4H(1), CbH2, CcH2, m), 3.27 (C4H
(2), dd, 2J = 18.3, 3J = 9.5), 7.48–7.43 (C4′H, m), 7.25–7.20 (C6′H,
m), 7.39 (C7′H, dt, 3J = 8.2, 4J = 5J = 0.9), 3.66 (C1xH2, t, 3J = 7.2),
1.76–1.66 (C2xH2, m), 1.63–1.52 (C3xH2, m), 2.44 (C4xH2, t, 3J = 7.5),
2.58 (CaH2, CdH2, bs), 7.19–7.11 (C3″H, C5″H, C2′H, C5′H m),
7.04–7.00 (C6″H, m), 7.04–6.94 (C4″H, m), 2.30 (CH3, s), 8.17
(N1′H, bs) 13C NMR (101 MHz, CDCl3) δ: 178.2 (C2), 38.2 (C3), 36.3
(C4), 176.5 (C5), 119.0 (C2′), 111.5 (C3′), 125.7 (C3′a), 122.2 (C4′),
120.1 (C5′), 122.7 (C6′), 111.7 (C7′), 136.6 (C7′a), 38.9 (C1x), 25.8
(C2x), 24.2 (C3x), 58.1 (C4x), 53.7 (Ca, Cd), 51.6 (Cb, Cc), 151.5 (C1″),
132.6 (C2″), 131.0 (C3″), 123.1 (C4″), 126.5 (C5″), 118.5 (C6″), 17.9
(CH3).
4.1.2.8. 1-(4-(4-(2,3-dimethylphenyl)piperazin-1-yl)butyl)-3-(1H-indol-3-
yl)pyrrolidine-2,5-dione (4h). The title compound was isolated as a
yellow solid. Yield: 76.3% (0.35 g); m.p. 70–78 °C; ESI-HRMS m/z calcd
for C28H34N4O2H (M+H)+ 459.2760, found: 459.2754; 1H NMR
(500 MHz, CDCl3) δ: 4.28–4.23 (C3H, m), 2.91 (C4H(1), dd,
2J = 18.5, 3J = 5.0), 3.22 (C4H(2), dd, 2J = 18.5, 3J = 9.5), 7.01
(C2′H, d, 3J = 2.5), 7.43 (C4′H, dd, 3J = 8.0, 4J = 0.5), 7.14–7.09
(C5′H, m), 7.23–7.18 (C6′H, m), 7.34 (C7′H, dt, 3J = 8.0, 4J =
5J = 1.0), 3.66 (C1xH2, t, 3J = 7.5), 1.76–1.65 (C2xH2, m), 1.62–1.52
(C3xH2, m), 2.44 (C4xH2, t, 3J = 7.5), 2.59 (CaH2, CdH2, bs), 2.89
(CbH2, CcH2, t), 6.90 (C4″H, C6″H, dd), 7.06 (C5″H, t, 3J = 8.0), 2.26
(2″-CH3, s), 2.21 (3″-CH3, s), 8.50 (N1′H, bs); 13C NMR (125 MHz,
CDCl3) δ: 178.3 (C2), 38.2 (C3), 36.3 (C4), 176.5 (C5), 118.5 (C2′),
111.4 (C3′), 125.7 (C3′a), 122.2 (C4′), 120.1 (C5′), 122.7 (C6′), 111.7
(C7′), 136.7 (C7′a), 39.0 (C1x), 25.9 (C2x), 24.2(C3x), 58.1 (C4x), 53.7
(Ca, Cd), 52.1 (Cb, Cc), 151.5 (C1″), 131.2 (C2″), 137.9 (C3″), 124.9
(C4″), 125.8 (C5″), 116.6 (C6″), 14.0 (2″-CH3), 20.6 (3″-CH3).
4.1.2.9. 3-(1H-indol-3-yl)-1-[4-[4-(2-methoxyphenyl)piperazin-1-yl]
butyl]pyrrolidine-2,5-dione (4i). The title compound was isolated as an
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orange solid. Yield: 73.0% (0.34 g); m.p. 58–62 °C; ESI-HRMS m/z calcd
for C27H32N4O3H (M+H)+ 461.2553, found: 461.2565; 1H NMR
(400 MHz, CDCl3) δ: 4.28 (C3H, 4d, 3J1 = 9.5, 3J2 = 4.9, 4J = 0.8),
2.92 (C4H(1), dd, 2J = 18.4, 3J = 4.8), 3.24 (C4H(2), dd, 2J = 18.3,
3J = 9.5), 7.06 (C2′H, dd, 3J = 2.6, 4J = 0.8), 7.47–7.41 (C4′H, m),
7.35 (C7′H, dt, 3J = 8.2, 4J = 0.9), 7.15–7.10 (C5′H, m), 7.24–7.18
(C6′H, m), 3.65 (C1xH2, t, 3J = 7.1), 1.75–1.66 (C2xH2, m), 1.64–1.54
(C3xH2, m), 2.51–2.45 (C4xH2, m), 2.67 (CaH2, CdH2, bs), 3.11 (CbH2,
CcH2, bs), 7.03–6.97 (C4″H, m), 6.95–6.90 (C3″H, C5″H, m), 6.88–6.84
(C6″H, m) 3.86 (OCH3, s), 8.51 (N1′H, bs); 13C NMR (101 MHz, CDCl3)
δ: 178.3 (C2), 38.1 (C3), 36.3 (C4), 176.5 (C5), 123.0 (C2′), 111.1 (C3′),
125.7 (C3′a), 118.5 (C4′), 120.1 (C5′), 122.2 (C6′), 111.7 (C7′), 136.6
(C7′a), 38.8 (C1x), 25.8 (C2x), 23.8 (C3x), 58.0 (C4x), 53.3 (Ca, Cd),
50.3 (Cb, Cc), 141.1 (C1″), 152.02 (C2″), 118.3 (C3″), 122.6 (C4″),
111.5 (C5″), 121.0 (C6″), 55.3 (OCH3).
4.1.2.10. 3-(1H-indol-3-yl)-1-[4-[4-(4-methoxyphenyl)piperazin-1-yl]
butyl]pyrrolidine-2,5-dione (4j). The title compound was isolated as a
greenish solid. Yield: 70.3% (0.32 g); m.p. 60–64 °C; ESI-HRMS m/z
calcd for C27H32N4O3Na (M+Na)+ 483.2372, found: 483.2360; 1H
NMR (400 MHz, CDCl3) δ: 4.29 (C3H, 4d, 3J1 = 9.5, 3J2 = 4.9,
4J = 0.8), 2.94 (C4H(1), dd, 2J = 18.4, 3J = 4.9), 3.26 (C4H(2), dd,
2J = 18.4, 3J = 9.5), 7.47–7.42 (C4′H, m), 7.16–7.11 (C2′H, C5′H, m),
7.38 (C7′H, dt, 3J = 8.2, 4J = 0.9), 7.26–7.19 (C6′H, m), 6.92–6.87
(C2″H, C6″H, m), 6.86–6.81 (C3″H, C5″H, m), 3.65 (C1xH2, t,
3J = 7.2), 1.75–1.65 (C2xH2, m), 1.61–1.51 (C3xH2, m), 2.46–2.39
(C4xH2, m), 2.61–2.55 (CaH2, CdH2, m), 3.10–3.05 (CbH2, CcH2, m),
3.77 (OCH3, s), 8.21 (N1′H, s); 13C NMR (101 MHz, CDCl3) δ: 178.2
(C2), 38.1 (C3), 36.3 (C4), 176.5 (C5), 125.7 (C2′), 111.7 (C3′), 118.5
(C3′a), 118.2 (C4′), 122.2 (C5′), 122.7 (C6′), 111.5 (C7′), 136.6 (C7′a),
39.9 (C1x), 25.8 (C2x), 24.1 (C3x), 58.0 (C4x), 53.3 (Ca, Ce), 50.5 (Cb,
Cd), 145.7 (C1″), 120.1 (C2″, C6″), 114.4 (C3″, C5″), 153.8 (C4″), 55.6
(OCH3).
4.1.2.11. 1-(4-(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)butyl)-
3-(1H-indol-3-yl)pyrrolidine-2,5-dione (4k). The title compound was
isolated as a yellowish solid. Yield: 59.2% (0.29 g); m.p. 75–82 °C
(melts with decomposition); ESI-HRMS m/z calcd for C28H32N4O4H (M
+H)+ 489.2502, found: 489.2490; 1H NMR (500 MHz, CDCl3) δ:
4.33–4.28 (C3H, m), 2.93 (C4H(1), dd, 2J = 18.0, 3J = 4.5), 3.26 (C4H
(2), dd, 2J = 18.0, 3J = 9.5), 6.84 (C2′H, d, 3J = 1.0), 7.45 (C4′H, dd,
3J = 8.0, 4J = 1.0), 7.14–7.09 (C5′H, C6″H, m), 7.22–7.17 (C6′H, m),
7.37 (C7′H, dt, 3J = 8.0, 4J = 5J = 1.0), 3.62 (C1xH2, t, 3J = 7.0),
1.72–1.63 (C2xH2, m), 1.62–1.49 (C3xH2, m), 2.47 (C4xH2, t, 3J = 8.0),
2.53 (CaH2, CbH2, CcH2, CdH2, bs), 3.43 (CeH2, s), 6.74 (C2″H, C5″H,
m), 5.94 (C7″H2, s), 8.44 (N1′H, bs); 13C NMR (125 MHz, CDCl3) δ:
178.3 (C2), 38.1 (C3), 36.3 (C4), 176.5 (C5), 118.6 (C2′), 111.6 (C3′),
125.7 (C3′a), 122.1 (C4′), 120.1 (C5′), 122.7 (C6′), 111.7 (C7′), 136.6
(C7′a), 38.5 (C1x), 25.5 (C2x), 23.3 (C3x), 57.6 (C4x), 52.7 (Ca, Cd),
52.0 (Cb, Cc), 62.4 (Ce), 131.3 (C1″), 107.9 (C2″), 147.7 (C3″), 146.8
(C4″), 109.6 (C5″), 122.4 (C6″), 100.9 (C7″).
4.1.2.12. 3-(1H-indol-3-yl)-1-[4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl]
pyrrolidine-2,5-dione (4l). The title compound was isolated as a white
solid. Yield: 53.4% (0.23 g); m.p. 56–65 °C (melts with decomposition);
ESI-HRMS m/z calcd for C24H28N6O2H (M+H)+ 433.2346, found:
433.2346; 1H NMR (500 MHz, CDCl3) δ: 4.29 (C3H, 4d, 3J1 = 9.5,
3J2 = 5.0, 4J = 0.4), 2.94 (C4H(1), dd, 2J = 18.5, 3J = 5.0), 3.26 (C4H
(2), dd, 2J = 18.0, 3J = 9.5), 7.13 (C2′H, dd, 3J = 2.0, 4J = 0.5), 7.44
(C4′H, dd, 3J = 8.0, 4J = 1.0, 5J = 0.5), 7.16–7.10 (C5′H, m),
7.25–7.19 (C6′H, m), 7.38 (C7′H, dt, 3J = 8.0, 4J = 5J = 1.0), 3.65
(C1xH2, t, 3J = 7.0), 1.76–1.65 (C2xH2, m), 1.62–1.50 (C3xH2, m), 2.43
(C4xH2, t, 3J = 7.5), 2.49 (CaH2, [4H], pt), 3.83 (CbH2, [4H], pt), 8.30
(C4″H, C6″H, d, 3J = 5.0), 6.48 (C5″H, t, 3J = 5.0), 8.32 (N1′H, bs);
13C NMR (125 MHz, CDCl3) δ: 178.1 (C2), 38.2 (C3), 36.4 (C4), 176.5
(C5), 122.1 (C2′), 111.7 (C3′), 125.7 (C3′a), 118.6 (C4′), 120.1 (C5′),
122.8 (C6′), 111.7 (C7′), 136.6 (C7′a), 38.8 (C1x), 25.8 (C2x), 24.0
(C3x), 58.0 (C4x), 53.0 (Ca, [2C]), 43.5 (Cb, [2C]), 161.6 (C2″), 157.7
(C4″, C6″), 109.9 (C5″).
4.1.2.13. 3-(1H-indol-3-yl)-1-[4-[4-(pyridin-2-yl)piperazin-1-yl]butyl]
pyrrolidine-2,5-dione (4m). The title compound was isolated as a white
solid. Yield: 49.6% (0.21 g); m.p. 50–56 °C (melts with decomposition);
ESI-HRMS m/z calcd for C25H29N5O2H (M+H)+ 432.2394, found:
432.2394; 1H NMR (500 MHz, CDCl3) δ: 4.29 (C3H, 4d, 3J1 = 9.5,
3J2 = 5.0, 4J = 1.0), 2.93 (C4H(1), dd, 2J = 18.0, 3J = 5.0), 3.26 (C4H
(2), dd, 2J = 18.0, 3J = 9.5), 7.12 (C2′H, dd, 3J = 2.5, 4J = 0.5), 7.44
(C4′H, 4d, 3J = 8.0, 4J = 2.0, 5J = 1.0), 7.17–7.09 (C5′H, m),
7.25–7.19 (C6′H, m), 7.37 (C7′H, dt, 3J = 8.0, 4J = 5J = 1.0), 3.65
(C1xH2, t, 3J = 7.0), 1.74–1.67 (C2xH2, m), 1.62–1.52 (C3xH2, m), 2.43
(C4xH2, t, 3J = 7.0), 2.53 (CaH2, [4H], pt), 3.53 (CbH2, [4H], pt),
6.68–6.62 (C3″H, C5″H, m), 7.47 (C4″H, 4d, 3J1 = 8.0, 3J2 = 7.0,
4J = 2.0), 8.19 (C6″H, 4d, 3J = 5.0, 4J = 2.0, 5J = 0.5), 8.38 (N1′H,
bs); 13C NMR (125 MHz, CDCl3) δ: 178.2 (C2), 38.2 (C3), 36.3 (C4),
176.5 (C5), 122.1 (C2′), 111.6 (C3′), 125.7 (C3′a), 118.6 (C4′), 120.1
(C5′), 122.7 (C6′), 111.7 (C7′), 136.7 (C7′a), 38.9 (C1x), 25.8 (C2x),
24.0 (C3x), 58.0 (C4x), 52.9 (Ca, [2C]), 45.1 (Cb,[2C]), 159.5 (C2″),
107.1 (C3″), 137.5 (C4″), 113.3 (C5″), 147.9 (C6″).
4.2. Radioligand binding assay
4.2.1. Preparation of solutions of test and reference compounds
1 mM stock solutions of tested compounds were prepared in DMSO.
Serial dilutions of compounds were prepared in 96-well microplate in
assay buffers using automated pipetting system epMotion 5070
(Eppendorf). Each compound was tested in 6 concentrations from 10 to
5 to 10–10 M (final concentration).
4.2.2. Serotonin transporter binding assay
Radioligand binding was performed using membranes from HEK-
293 cells stably transfected with the human serotonin transporter
(PerkinElmer). All assays were carried out in duplicates. 50 µL working
solution of the tested compounds, 50 µL [3H]-imipramine (final con-
centration 2 nM) and 150 µL diluted membranes (9 µg protein per well)
prepared in assay buffer (50 mM Tris, pH 7.4, 5 mM KCl, 120 mM NaCl)
were transferred to polypropylene 96-well microplate using 96-wells
pipetting station Rainin Liquidator (MettlerToledo). Imipramine
(10 μM) was used to define nonspecific binding. Microplate was cov-
ered with a sealing tape, mixed and incubated for 30 min at 27 °C. The
reaction was terminated by rapid filtration through GF/C filter mate
presoaked with 0.5% polyethyleneimine for 30 min. Ten rapid washes
with 200 µL 50 mM Tris buffer, 154 mM NaCl (4 °C, pH 7.4) were
performed using automated harvester system Harvester-96 MACH III
FM (Tomtec). The filter mates were dried at 37 °C in forced air fan
incubator and then solid scintillator MeltiLex was melted on filter mates
at 90 °C for 4 min. Radioactivity was counted in MicroBeta2 scintilla-
tion counter (PerkinElmer). Data were fitted to a one-site curve-fitting
equation with Prism 6 (GraphPad Software) and Ki values were esti-
mated from the Cheng-Prusoff equation.
4.2.3. 5-HT1A receptor binding assay
Radioligand binding was performed using membranes from CHO-K1
cells stably transfected with the human 5-HT1A receptor (PerkinElmer).
All assays were carried out in duplicates. 50 µL working solution of the
tested compounds, 50 µL [3H]-8-OH-DPAT (final concentration 1 nM)
and 150 µL diluted membranes (10 µg protein per well) prepared in
assay buffer (50 mM Tris, pH 7.4, 10 mM MgSO4, 0.5 mM EDTA, 0.1%
ascorbic acid) were transferred to polypropylene 96-well microplate
using 96-wells pipetting station Rainin Liquidator (MettlerToledo).
Serotonin (10 μM) was used to define nonspecific binding. Microplate
was covered with a sealing tape, mixed and incubated for 60 min at
27 °C. The reaction was terminated by rapid filtration through GF/C
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filter mate presoaked with 0.3% polyethyleneimine for 30 min. Ten
rapid washes with 200 µL 50 mM Tris buffer (4 °C, pH 7.4) were per-
formed using automated harvester system Harvester-96 MACH III FM
(Tomtec). The filter mates were dried at 37 °C in forced air fan in-
cubator and then solid scintillator MeltiLex was melted on filter mates
at 90 °C for 4 min. Radioactivity was counted in MicroBeta2 scintilla-
tion counter (PerkinElmer). Data were fitted to a one-site curve-fitting
equation with Prism 6 (GraphPad Software) and Ki values were esti-
mated from the Cheng-Prusoff equation.
4.2.4. D2 receptor binding assay
Radioligand binding was performed using membranes from CHO-K1
cells stably transfected with the human D2 receptor (LifeTechnologies).
All assays were carried out in duplicates. 50 µL working solution of the
tested compounds, 50 µL [3H]-methylspiperone (final concentration
1 nM) and 150 µL diluted membranes (5 µg protein per well) prepared
in assay buffer (50 mM HEPES, pH 7.4, 50 mM NaCl, 5 mM MgCl2,
0.5 mM EDTA) were transferred to 96-well microplate. Haloperidol
(10 μM) was used to define nonspecific binding. Microplate was cov-
ered with a sealing tape, mixed and incubated for 60 min at 37 °C. The
reaction was terminated by rapid filtration through GF/C filter mate
presoaked with 0.5% polyethyleneimine for 30 min. Ten rapid washes
with 200 µL 50 mM Tris buffer (4 °C, pH 7.4) were performed using
automated harvester system Harvester-96 MACH III FM (Tomtec). The
filter mates were dried at 37 °C in forced air fan incubator and then
solid scintillator MeltiLex was melted on filter mates at 90 °C for 4 min.
Radioactivity was counted in MicroBeta2 scintillation counter
(PerkinElmer). Data were fitted to a one-site curve-fitting equation with
Prism 6 (GraphPad Software) and Ki values were estimated from the
Cheng-Prusoff equation.
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